Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(applications tested for the base form of this product only)
Specificity and Use
NR1H4 / FXR antibody was raised against synthetic peptide located between aa33-82 of human NR1H4 (G8JLB0). Percent identity by BLAST analysis: Human, Chimpanzee, Gibbon, Monkey, Rabbit, Horse, Pig (100%); Mouse, Dog, Bovine (92%).
NR1H4 Antibody, BAR Antibody, Farnesyl x receptor Antibody, FXR Antibody, HRR1 Antibody, Farnesoid x activated receptor Antibody, Farnesoid X receptor Antibody, Farnesol receptor HRR-1 Antibody, HRR-1 Antibody, RXR-interacting protein 14 Antibody, RIP14 Antibody, Bile acid receptor Antibody, Farnesoid X nuclear receptor Antibody, Farnesoid X-activated receptor Antibody
Farnesoid X receptor (FXR), a NR1 Thyroid Hormone-Like Receptor, has been shown to affect bile-acid metabolism in the liver and intestine. FXR binds to target DNA as a heterodimer (with retinoid X receptors) and is activated by bile acids. Binding of bile acids to the RXR/FXR heterodimer in liver represses CYP7A1 expression and bile-acid production, leading to a failure to solubilize and absorb cholesterol.